
Karolinska Development Investor Relations Material
Latest events

Q1 2025
30 Apr, 2025

Q4 2024
14 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Karolinska Development
Access all reports
Karolinska Development AB is a Sweden-based investment company that plays a significant role in the biotechnology sector. It is primarily engaged in providing capital, developing, and commercializing biotechnological products. The company's activities span a broad range of medical and therapeutic areas, including oncology, infections and wound healing, women’s health, cardiovascular and hematology, as well as medical equipment and diagnostics. Karolinska Development AB showcases a diverse portfolio that comprises investments in pharmaceutical research and development, healthcare technology, gene research and development, drug delivery technologies, and life sciences tools, among others. Founded in 2003 and with a modest team, the company focuses on fostering innovation and advancing the development of new treatments and medical solutions. The company is headquartered in Solna, Sweden, and its shares are listed on the Stockholm Stock Exchange.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
KDEV
Country
🇸🇪 Sweden